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Abstract
Background: The timely publication of findings in peer-reviewed journals is a primary goal of clinical research. In
clinical trials, the processes leading to publication can be complex from choice and prioritization of analytic topics
through to journal submission and revisions. As little literature exists on the publication process for multicenter
trials, we describe the development, implementation, and effectiveness of such a process in a multicenter trial.
Methods: The Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) trial included a data coordinating
center (DCC) and clinical centers that recruited and followed more than 1,000 patients. Publication guidelines were
approved by the steering committee, and the publications committee monitored the publication process from
selection of topics to publication.
Results: A total of 73 manuscripts were published in 23 peer-reviewed journals. When manuscripts were closely
tracked, the median time for analyses and drafting of manuscripts was 8 months. The median time for data analyses
was 5 months and the median time for manuscript drafting was 3 months. The median time for publications
committee review, submission, and journal acceptance was 7 months, and the median time from analytic start to
journal acceptance was 18 months.
Conclusions: Effective publication guidelines must be comprehensive, implemented early in a trial, and require active
management by study investigators. Successful collaboration, such as in the HALT-C trial, can serve as a model for
others involved in multidisciplinary and multicenter research programs.
Trial registration: The HALT-C Trial was registered with clinicaltrials.gov (NCT00006164).
Keywords: Publication guidelines, Publication processes, Publication management, HALT-C trial, Authorship assignment,
Authorship allocation
Background
Well-designed clinical trials are essential to providing in-
formation needed by the medical and scientific communi-
ties in order to adapt or change treatments. Peer-reviewed
scientific publications - the primary modes of communi-
cation among scientists - are an important measure of a
clinical trial’s contribution to science. Hence the quality of
such publications should be maximized. In a large-scale,
long-term collaborative study, the potential exists for
many papers to be prepared and published. For multicen-
ter clinical trials that may involve thousands of study sub-
jects and hundreds of investigators worldwide, timely
publication of research findings can be complex and
challenging, from choice and prioritization of analytic
topics through to journal submission and revisions [1,2].
Therefore the recommendation has been made that large
study groups prospectively develop a formal policy speci-
fying authorship guidelines to avoid unpleasant surprises
and controversies during manuscript preparation [3,4].
There are few scientific publications detailing strategies to
promote publication timeliness in collaborative studies
and no publications on planning multiple publications of
inter-related data collected from a single population of
study patients [5-8]. In large-group multidisciplinary
health sciences research, authorship allocation based on
predefined principles ensures appropriate acknowledg-
ment for individual responsibility and contribution to a
publication, necessitating guidelines for planning author-
ship assignments and publications [9].
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Cirrhosis (HALT-C) trial was a National Institutes of
Health (NIH) sponsored Phase III randomized controlled
trial spanning a 14-year time period. The HALT-C trial
Group was comprised of 290 study-affiliated investigators,
collaborators, and staff members. The collection of an
enormous amount of data, and interest in using the data
for secondary analyses, necessitated the establishment of a
system for publication planning and management. The
HALT-C trial group developed processes to guide collabo-
rators through topic selection, equitable assignment of
authorship duties and authorship order, analysis pri-
oritization, and eventual publication of study data. The
procedural approach allowed a transparent process that
collaborating researchers accepted readily. Through open,
proactive, and frequent communication of current and
planned publications, the HALT-C trial group sought
to preemptively limit conflicts, avoid bottlenecks, and
reduce tension among colleagues. Herein, we describe
the HALT-C trial publication processes, which may
prove a useful model for scientists and administrators
faced with data collection, analysis, and manuscript-
prioritization decisions in other complex studies with
large databases of interrelated data on one population
of study patients.
Methods
Background
The HALT-C trial was sponsored by the National Insti-
tute of Diabetes and Digestive and Kidney Diseases
(NIDDK), NIH. Initial study funding began in November
1999, with 10 clinical center sites (CCs) contracted
across the United States. Separately, NIDDK funded a
central specimen repository (SeraCare Life Sciences,
Gaithersburg, Maryland, United States), a central virology
laboratory (at the University of Washington, Seattle,
Washington, United States), and a data coordinating center
(DCC) (at New England Research Institutes, Watertown,
Massachusetts, United States). Recruitment began in study
year 1 (2000) and ended in study year 5 (2004). Patient
follow-up for the randomized phase ended in study year 8
(2007), but patients continued to be followed until the end
of study year 9 (2008). CC funding ended in study year 12
(2011) and DCC funding ended in study year 14 (2013).
The study investigators established several committees
of which two are relevant to the current paper. A steer-
ing committee, whose membership consisted of a single
lead investigator from each of the 13 independent sites
(10 CCs, the virology laboratory, the DCC, and NIDDK
project office), was responsible for study oversight in-
cluding management of sub-committees. The publica-
tions committee maintained oversight of publications
and presentations and was comprised of a representative
from each of the sites.
The design of the HALT-C main trial has been previ-
ously described [10,11]. The aim of the trial was to de-
termine whether long-term peginterferon therapy could
reduce the progression of advanced chronic hepatitis C
(CHC) in previous non-responders to interferon-based
therapy and whether the anticipated benefits would jus-
tify the risks, inconvenience, and expense involved.
HALT-C had two major treatment phases and an ob-
servational phase. A lead-in phase used full dose pegin-
terferon alfa-2a and ribavirin to attempt to achieve
sustained virological response (SVR) among patients
with advanced liver disease (defined as an Ishak fibrosis
score of 3 or greater upon liver biopsy) who had previ-
ously been treated with standard interferon with or with-
out ribavirin. Patients who did not achieve SVR were
eligible for the randomized phase; a controlled clinical
trial of peginterferon alfa-2a at a dosage of 90 μg per
week for 3.5 years, as compared with no treatment. The
primary endpoint was progression of liver disease as in-
dicated by death, hepatocellular carcinoma, hepatic de-
compensation, or, for those with bridging fibrosis at
baseline, an increase in the Ishak fibrosis score of 2 or
more points. The difference between the treated and un-
treated groups in the rates of the primary endpoint was
not statistically significant (hazard ratio - 1.01; 95% CI =
0.81 to 1.26, P =0.91) [11]. Patients continued to be
followed in the observational phase for clinical outcomes
off therapy for as long as five additional years. The study
was approved by the institutional review boards of each
participating institution (Additional file 1) and registered
with ClinicalTrials.gov (NCT00006164). All study pa-
tients provided written informed consent for participa-
tion in the trial.
In addition to the main trial, 41 ancillary studies were
designed and conducted during which additional data
and/or biological samples were collected and analyzed.
Some ancillary studies included all enrolled trial pa-
tients, while others were conducted at selected CCs or
involved a subset of patients. For the HALT-C main trial
and ancillary studies, 146 different case report forms
were developed and deployed over the course of the
research period. A total of 33,072 patient visits and
371,684 individual case report forms were entered into
the central database. In addition, 400,848 specimen sam-
ples were collected by investigators from trial subjects
for storage by the central repository or for testing at the
central virology laboratory. All collected data were made
available for analyses.
Publication goals
The overarching publication goal of the HALT-C trial
was to disseminate the key study results to the scientific
community in a timely fashion. With this goal in mind,
the steering committee and publications committee had
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authorship across multiple investigators, the best prac-
tices for selection of analyses and publication topics, the
order and prioritization of conducting statistical analyses
by the DCC, and the promotion of successful, collegial
collaboration.
The DCC was tasked with managing the coordination
of publication processes, effective facilitation of writing
group interactions, determination of analysis prioritiza-
tion (with investigator approval), completion of all desired
analyses and manuscripts in a timely fashion, maintenance
of data, analytic, and publication quality, and helping the
entire study team to collaborate successfully.
Publication guidelines
The publications committee chair used guidelines from
older NIH studies to develop the HALT-C publication
and presentation guidelines. After review by publications
committee members, version 1 of the guidelines was ini-
tially approved by the steering committee in study year
1. The guidelines underwent two amendments in study
year 2 and 3, which added authorship guidelines for
non-HALT-C investigators (version 2) and required in-
clusion of a financial disclosure paragraph in all manu-
scripts (version 3), along with other minor clarifications
(see Additional file 2 for the final version of the guide-
lines). The guidelines provided the basis and reference
document to support the publication of HALT-C trial
research results and established standard procedures for
authorship. The guidelines were designed to achieve six
goals. First, to promote the timely and high-quality pres-
entation and publication of findings. Second, to support
broad and equitable participation by HALT-C trial inves-
tigators in presentations and publications. Third, to pro-
spectively define a set of equitable rules and guidelines
to determine authorship and the order in which authors
are listed. Fourth, to select topics for publication and
presentation, assign authors to writing groups, and set
priorities for publications and presentations. Fifth, to
provide editorial support and timely review for presenta-
tions and publications. Sixth, to defend the academic
freedom of HALT-C trial investigators to publish results
emanating from the trial while providing limitations on
the premature dissemination of results that could
threaten the integrity of collective data and jeopardize
publication in high-impact journals.
Results
The HALT-C trial group developed organizational proce-
dures and processes to facilitate analyses and publications
during the course of the trial. First, the actions of the pub-
lications committee during the study are described
followed by information on resulting publications.
Publications committee actions
Writing groups
Manuscript writing was assigned to a writing group con-
sisting of three to four investigators, one of whom was
designated the writing group Chair and responsible au-
thor, as well as a DCC statistician. The publications
committee nominated the writing group members which
was followed by approval from the steering committee.
The publications committee Chair ensured equitable as-
signments to writing groups over the course of the
study. In the opinion of the authors, limiting each writ-
ing group to a maximum of four investigators was a key
factor in the efficiency of the writing groups.
Manuscript concept sheets
The publications committee planned a ‘main outcome’
paper addressing the primary objective of the HALT-C
trial: the impact of long-term antiviral therapy on pre-
cirrhotic and cirrhotic CHC [11]. For other papers, the
publications committee asked investigators to suggest
topics by submitting manuscript concept sheets (MCSs)
to the publications committee. The DCC developed a
two-page MCS template which included a brief descrip-
tion of the background, hypothesis and purpose, a defin-
ition of the subjects to be included, a list of variables of
interest, and planned statistical analyses. In practice an
investigator drafted the MCS with statistical input from
the DCC. The publications committee judged each MCS
on scientific merit, availability of appropriate data, and
ability of the DCC to accommodate the analyses. If an
overlap in content existed between two proposals, a con-
solidated MCS was developed with oversight by the
Publications Committee. Interested collaborators were
solicited to form the proposed writing group. Writing
group membership could be altered or augmented by
the publications committee.
At the peak of publications planning during study year
7, 60 MCSs were submitted and reviewed at an in-
person steering committee meeting. After consolidation
of some topics and removal of other topics that had in-
sufficient data or limited scientific interest, 40 MCSs
were approved by consensus. Investigators were then
asked to indicate their top four choices of interest. The
publications committee Chair then assigned investiga-
tors to manuscripts, balancing investigators across the
CCs, with subsequent approval of these assignments by
the steering committee. Use of the MCS process reduced
overlap between and among manuscripts and provided a
means for equitable authorship assignment.
Prioritization of topics and analyses
The publications committee categorized MCSs into the
three manuscript categories: (1) Study-wide main papers
that represented reports of the main outcomes of the
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all CCs. (2) Secondary papers that addressed issues more
peripheral to the main study outcomes but that were
based on data collected as part of the main study at all
CCs. This category included ancillary studies that were
conducted at all CCs. (3) Local papers that represent
reports of data collected from locally initiated and separ-
ately conducted ancillary studies unique to one or sev-
eral CCs.
Within each of the three categories, MCSs were further
prioritized into high, medium, and low levels based on
importance of the topic. The steering committee initially
approved priority levels at an in-person meeting. Priority
levels were reviewed regularly and were subject to revi-
sion by the steering committee. For each new analysis
the DCC started the analysis in order of the assigned
priority level (from highest priority to lowest).
The DCC provided information on the number of ana-
lyses that could be conducted concurrently based on the
capacity for support by DCC staff and statisticians, and
whether all approved analyses could be completed
within the timeframe of study funding. The DCC fore-
casted the capacity for conducting analyses based on an-
nual contract funding and staffing levels, with each
statistician assigned to between two and four analyses at
a time.
Further, the publications committee solicited feedback
from the DCC when papers were taking more analytic
time than anticipated, or when writing groups were slow
to complete milestones. During study year 7 statistical
requests and workload increased because final study re-
sults were expected in study year 8. In response, the
DCC developed a manuscript timelines spreadsheet
that listed all ongoing analyses being conducted, with
information on stage of analysis (Figure 1). The spread-
sheet was updated and distributed monthly to the pub-
lications committee and steering committee, which
allowed for the easier review and forecasting of up-
coming work. This process was effective in forecasting
DCC capacity and resource allocation within budget
and staffing constraints.
Analysis and writing processes
The publications committee agreed that all papers
should present a coherent message, therefore, a list of
approved study outcome definitions was developed with
input from the DCC statisticians. The primary and sec-
ondary outcomes of the randomized trial were defined
in the protocol and the statistical analysis plan, and all
other analyses for any publication were required to use
the approved outcomes. Some publications used alter-
nate outcome definitions that had not been included in
the protocol. Alternate outcome definitions were pro-
posed by writing groups, reviewed by the DCC, and then
required publications committee approval. As the study
follow-up time was extended, additional outcome defini-
tions were added to define the time intervals for survival
analyses. The publications committee informed ongoing
writing groups when new outcome definitions were ap-
proved for use.
When a MCS came up in the priority-based queue, a
standard 14-step process was followed by the writing
group and assigned DCC statistician: (1) The statistician
drafted a detailed analysis plan (AP), which included de-
scriptions of the cases to be included, planned variables,
analytic approaches, and mock tables; (2) The writing
group and statistician reviewed, revised, and approved
the AP, with the understanding that the group had to ad-
here to the AP; (3) The statistician performed analyses
according to the AP, soliciting help from other statisti-
cians as needed; (4) The statistician prepared summaries
of the results for discussion by the writing group; (5)
Writing group conference calls were scheduled at least
once per month to review analytic results and tables.
Writing group sessions were also built into the agendas
of semiannual in-person steering committee meetings.
Regular attendance and active participation in meetings
and teleconferences were expected; (6) The writing
group Chair directed the analyses of each manuscript.
He or she worked one-on-one with the statistician, and
all analysis requests went through the Chair; (7) The
writing group Chair directed the writing of each manu-
script. He or she prepared action items, assigned writing
and reviewer tasks, and was responsible for overseeing
the completion of tasks on schedule. The statistician
assisted with drafting assigned sections of the manu-
script and preparing all tables and figures; (8) The DCC
assisted the writing group Chair with scheduling calls
and meetings. The DCC sent reminders two to three
days prior to each meeting, along with all associated ma-
terials to be reviewed; (9) The DCC held weekly statis-
tical team meetings to review timelines, facilitate cross
discussion of related analyses, and offer help with writ-
ing group interactions; (10) A second DCC statistician
performed quality control review of analyses to ensure
accuracy of programming and data presented in the final
manuscript; (11) The writing group Chair reported on
the current status of manuscript preparation at monthly
publications committee and steering committee calls. If
progress was stalled, committee members discussed op-
tions and workarounds, including the possibility of the
replacement of writing group members or a change in
the analysis priority level; (12) The writing group Chair
finalized the manuscript with input from all co-authors
and the DCC forwarded the manuscript to the publica-
tions committee and NIDDK for review; (13) The writ-
ing group Chair was responsible for addressing internal
reviewer comments and submitting the manuscript to
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sponsible for responding to any journal editor and out-
side reviewer comments and for resubmission. The
statistician performed re-analyses as needed. Analyses of
manuscripts being revised for resubmission received
high priority.
Data use agreements
In study year 7, the steering committee agreed to allow
the sharing of analytic datasets with approved investiga-
tors which permitted the generation of additional
manuscripts, especially in topics and disciplines requir-
ing specialty statistical input (such as Genome Wide As-
sociation Studies). The steering committee developed a
data use agreement (DUA) template, which was com-
pleted by interested investigators (Additional file 3). A
DUA was reviewed by the DCC to determine whether
requested data were available and to estimate the
amount of time required to produce the requested data-
set. The steering committee and NIDDK then approved
the DUA. After a dataset was provided, analyses were
conducted by a non-DCC statistician. A DCC statistician
Manuscript JA SO N DJFM A M JJA SO N DJFM A M JJA SO N DJFM A M JJA SO N DJFM A M JJA SO N DJFM A
Study-wide
A-01
A-02
A-03
A-04
A-05
A-06
A-07
A-08
A-09
A-10
A-11
A-12
A-13
A-14
A-15
Local
B-01
B-02
B-03
B-04
B-05
B-06
B-07
Secondary
C-01
C-02
C-03
C-04
C-05
C-06
C-07
C-08
C-09
C-10
C-11
DUA
D-01
D-02
D-03
D-04
D-05
D-06
D-07
D-08
D-09
D-10
Year 14 Year 13  Year 9 Year 10 Year 11 Year 12
KEY
Draft and approve Analysis Plan
Analyses by DCC statistician
Writing Group drafts manuscript
Manuscript to Publications Committee and journal, includes resubmissions
Journal acceptance
Dataset sent by DCC under Data Use Agreement
Analyses by non-DCC statistician per Data Use Agreement
Figure 1 HALT-C manuscript timelines. This figure includes publications that were tracked starting in July of study year 9. Thirty-three publications,
classified as study-wide, local, or secondary, were analyzed at the DCC and ten publications were analyzed at other institutions using a DUA. The color
codes indicate the activity stage. DCC, data coordinating center; DUA, data use agreement.
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drafted manuscript. The resulting manuscript underwent
publications committee review following the standard
process.
Authorship attribution
The decision-making process for authorship attribution
and order of authors was outlined a priori in the publi-
cation guidelines. The guidelines contained the clear
statement that ‘Authors should participate in the writing
of the paper according to guidelines of the International
Committee of Medical Journal Editors’ (ICMJE) [12].
The ICMJE guidelines stipulate that authorship requires
involvement in planning, analysis, or writing of the
manuscript, contribution to concept, design, and ana-
lysis, a role in the drafting of the article and/or revising
it critically for important intellectual content, and final
approval of the version to be published. The writing
group Chair controlled task allocation in writing the
paper and acted as a gatekeeper in the attribution of
authorship and authorship order, based on the division
of labor during the writing of the paper. Each manu-
script’s statistician was included as an author. Additional
authors were listed in order of the number of patients
enrolled at the corresponding site, in adherence to publi-
cations committee guidelines, which also allowed for the
designation of a different author order based on excep-
tional effort and input during manuscript preparation.
The publications committee Chair was also consulted if
necessary.
Editorial processes
Each fully drafted manuscript was submitted to the pub-
lications committee and NIDDK for review. Two publi-
cations committee members who were not members of
the writing group for the paper were designated to pro-
vide a timely in-depth review for editorial clarity and
data integrity. All modifications requested by the publi-
cations committee members or in-depth reviewers were
sent to the writing group Chair to address. The manu-
script was submitted for publication after obtaining ap-
proval from all authors, the publications committee, and
NIDDK.
Administrative processes
To help the writing group Chair with the administrative
details of manuscript submission, the DCC developed
the supplementary sections for every paper. These sec-
tions contained each author’s name, degree, institutional
affiliation, acknowledgments of study funding sources,
acknowledgments of appropriate study personnel, and fi-
nancial disclosures paragraphs.
To protect the publication process from a real or appar-
ent conflict of interest, all investigators, co-investigators,
and manuscript co-authors were required to disclose all
relationships with pharmaceutical companies or other
relevant entities. The DCC coordinated this annual dis-
closure process and maintained a log of all potential con-
flicts of interests. The DCC used this log to draft a
financial disclosure section for each manuscript. Each co-
author was required to review and confirm that the dis-
closure information was up-to-date for each manuscript.
Contributors who did not meet the criteria for author-
ship, but nevertheless contributed to the development of
the research or manuscript, were listed in the acknowl-
edgments section of each paper. The list of contributors
was maintained by the DCC. Each principal investigator
was responsible for reviewing and approving the inclu-
sion of acknowledged persons from their CC on every
paper.
The supplemental sections were distributed for review
and approval prior to their insertion into the final manu-
script for journal submission. The DCC collaborated
with the writing group Chair to ensure that these sec-
tions were accurate in the submission version of the
manuscript.
HALT-C publications
The publications committee assigned a writing group to
develop the HALT-C trial design manuscript in study
year 3 [10]. The paper provided detailed information on
study design, hypotheses, outcomes, inclusion and exclu-
sion criteria, sample size and power calculations, study
execution, and numbers of patients screened, random-
ized, and followed. Publication of this paper early in the
study cycle provided a citation for use in all subsequent
papers about basic information on study design.
The HALT-C trial main outcome manuscript received
top analytic priority and was produced efficiently, fol-
lowing the processes described above [11]. Introductory
sections were drafted and tables predefined by the writ-
ing group. An analytic plan for statistical programming
was adopted that allowed rapid data analyses after data
lock occurred in study year 8. The manuscript was writ-
ten, reviewed, and approved quickly; and submitted and
accepted by a leading journal nine months later, despite
the null results of the primary outcome. During the time
between initial submission and acceptance by the jour-
nal, the writing group responded to three requests for
additional analyses or revisions by reviewers. The paper
was published five months after acceptance.
Including the design and main outcome papers, 73 pa-
pers and one letter were published in 23 peer-reviewed
journals across the fields of general medicine, gastro-
enterology and hepatology, psychiatry, virology, and clin-
ical trials (Table 1) [10,11,13-78]. A total of 28 of the 74
publications were study-wide main papers that repre-
sented main outcomes of the trial, 25 were secondary
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these papers were published during a three-year period
after the randomized trial was completed (Figure 2A). A
total of 64 of the 74 publications were analyzed by the
DCC. The remaining 10 were prepared under a DUA
but were considered important to the study and were
tracked by the publications committee. One manuscript
prepared under a DUA and tracked by the publications
committee was rejected by one journal and has not been
submitted to another journal.
Of the 74 publications, 35 different investigators were
first authors. First authors came from all 13 sites that
were represented on the steering committee, a testament
to the intellectual engagement from all centers in the
study. A total of 123 investigators were authors at least
once among the total of 776 co-authors listed on all
publications. Co-authors included members of the man-
uscript’s writing group and others who had contributed
to the publication, as specified in the guidelines.
The publications guidelines also described procedures
for the submission of abstracts to meetings of profes-
sional societies. Proposals for abstracts had to be sub-
mitted to the publications committee six weeks before
the submission deadline so that the DCC could deter-
mine the workload. Drafts of the abstract had to be sub-
mitted to the publications committee seven days before
this deadline. Between study year 1 and study year 11, 55
abstracts were accepted for presentation at annual meet-
ings (Figure 2B). Most of these abstracts were linked to
manuscript proposals and all were eventually included in
a publication. The median time from abstract presentation
to publication was 1.5 years, range 0.25 to 4.75 years.
The DCC tracked progress of manuscript proposals
during the most active period of analysis and publications
when more than two dozen proposals were planned (study
Table 1 HALT-C publications by journal
Journal names Number of
publications
Number
of unique
first authors
2012
impact
factor
1. New England Journal
of Medicine
1 1 53.30
2. Gastroenterology 14 10 11.68
3. Hepatology 21 14 11.67
4. Gut 1 1 10.11
5. Journal of Hepatology 4 4 9.26
6. American Journal
of Gastroenterology
6 3 7.28
7. Journal of Infectious Diseases 1 1 6.41
8. Clinical Gastroenterology
Hepatology
4 4 5.63
9. Gastrointestinal Endoscopy 1 1 4.88
10. Journal of Clinical
Microbiology
1 1 4.15
11. PLoS One 3 3 4.09
12. Journal of Viral Hepatitis 2 2 4.09
13. Liver International 1 1 3.82
14. Alimentary Pharmacology
Therapeutics
5 3 3.77
15. J Affect Disorders 1 1 3.52
16. Pharmacogenetics
and Genomics
1 1 3.49
17. Journal of International
Neuropsychology Society
1 1 2.76
18. Clinical Trials 1 1 2.36
19. Virology Journal 1 1 2.34
20. Journal of Clinical
Experimental Neuropsychology
1 1 2.13
21. Psychosomatics 1 1 2.12
22. Digestive Disease Sciences 1 1 2.12
23. Contemporary Clinical Trials 1 1 1.81
TOTAL 74
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Figure 2 Number of HALT-C publications and abstracts by year
published. A: The light grey portions are for the 36 publications
that used only baseline or lead-in phase data and the dark grey
portions are for the 38 publications using data from the randomized
phase of the HALT-C trial. B: The light grey portions are for the 33
abstracts that used only baseline or lead-in phase data and the dark
grey portions are for the 22 abstracts using data from the randomized
phase of the HALT-C trial. Study year represents the number of years
from the start of the study.
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equivalent of four full time biostatisticians contributed to
the publication effort. A total of 33 proposals were initi-
ated, analysis plans were prepared, statistical analysis by a
DCC statistician conducted, and a manuscript draft pre-
pared for publications committee review. The median
time for these steps was 8 months (range 3 to 28 months).
The bulk of this time was taken up by data analysis (me-
dian 5.0 months; range 1 to 17 months) and manuscript
preparation by the writing group (median 3.0 months;
range 1 to 21 months). Time from submission to the pub-
lications committee to acceptance by a journal ranged
from 1 to 33 months (median 7 months), and the median
total time from analysis to acceptance was 18 months
(range 5 to 57). Figure 3 shows the cumulative distribution
of the time from the start of analysis to acceptance by a
journal for these 33 publications. The first 32 publications
were not included in either Figure 1 or Figure 3 because
these publications were being prepared during a time
when the analysis workload was relatively light and the
DCC did not track their progress. One of these 32 was the
primary results manuscript, which was not included be-
cause of the constraints imposed by having to wait for the
final data lock to complete the analyses.
During the course of the trial, investigators of other
NIH-sponsored multicenter trials requested access to
the HALT-C trial publication and presentation guide-
lines. These requests were submitted to the publications
committee, which approved sharing of the document as
long as attribution to the HALT-C trial was disclosed.
The guidelines document is included as Additional file 2,
and may be used by other trials with attribution.
Discussion
Effective publication guidelines must be comprehensive,
must be implemented early in a trial, and require active
management by study investigators. The HALT-C trial
goals were met through developing and following publi-
cations processes, with collaboration and compromise
by collaborators. Paramount in this detailed process was
the high priority placed on anticipation and preemption
of potential publication problems and conflicts. Dis-
agreements among investigators over authorship partici-
pation and order were avoided by adhering to the
approved publication guidelines.
Despite our best efforts, the processes did not always
work optimally. Some manuscripts took longer to pro-
duce than anticipated, resulting from delays at the levels
of analysis, writing, review, or submission. In two in-
stances, the publications committee replaced a writing
group Chair when the writing process lagged. The DCC
could not always accommodate requests for analyses in
order to meet conference deadlines for abstract submis-
sions as analyses for higher priority manuscripts had
precedence. Similarly, the DCC could not accommodate
requests for lower level priority MCSs when all statisti-
cian effort was committed to higher priority MCSs. If in-
vestigators expressed impatience with timing of analyses,
the DCC could request a review of priorities and assist-
ance in resolving disputes from the steering committee
or the publications committee.
Our analysis of the time interval from the start of ana-
lysis to journal acceptance included only the last 33
manuscripts prepared by the DCC statisticians. This
time interval would likely have been somewhat longer if
we had included the earlier manuscripts that were pre-
pared at a time when there was less pressure for timely
publication.
In spite of the large scope, 14-year duration, and com-
plexity of the trial, the HALT-C trial group developed
guidelines and processes that allowed the group to as-
sign authorship equitably, select publication topics col-
laboratively, determine priorities for analyses, facilitate
writing group activities, and promote a high degree of
productivity, culminating in the publication of 73 papers
and one letter (and the supporting abstracts and presen-
tations prepared during their development). All HALT-C
results presented in abstract form were subsequently
published in full, a rate far higher than that found in
other studies [79,80].
The processes that proved most effective at accom-
plishing the publication goals were the following: re-
quirement for formal MCSs and APs, assignment of
small, focused writing groups that adhered to approved
outcome definitions, analytic prioritization assigned by
the publications committee and tracked on a manuscript
timelines spreadsheet, and tight control of publications
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Figure 3 Cumulative distribution of time from start of analysis
to journal acceptance. These 33 HALT-C publications, closely
tracked by the publications committee, had a median time from
start of analysis to acceptance of 18 months (range 5 to 57).
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journal submission.
The HALT-C trial publication processes allowed for
effective dissemination of study results to be published
in a broad range of high-quality journals in a timely
fashion [5,7,8,79,81]. The findings of the HALT-C trial
have had important implications for the treatment of pa-
tients with treatment-resistant, histologically advanced
chronic hepatitis [11].
Further, study results were published in other scientific
areas beyond the field of gastroenterology, including
microbiology, neuropsychology, and pharmacogenomics.
The number and quality of manuscripts published justi-
fied the funding and effort devoted to the study over
14 years. The rich HALT-C trial database, as well as the
remaining biological specimens and genetic data, have
been submitted to the NIDDK Repository and are avail-
able for other researchers to investigate and query [82].
The HALT-C trial should continue to be a valuable
source of scientific data and biospecimens for future in-
vestigation and years to come [83].
Conclusions
Group, team, collaborative, or network studies are be-
coming more frequent in health-sciences research. Good
coordination and planning are necessary to assure
timely, complete, and accurate reporting of results to the
scientific community, as well as to avoid tensions and
conflicts that can arise in the context of analysis of a
large collaborative research study. Adherence to our or-
ganized publication processes led to success in achieving
these goals. Although not planned to be a generalizable
system, our example of how such collaboration was
achieved successfully in the HALT-C trial can be useful
as a model for others involved in or planning multidis-
ciplinary and multicenter research programs.
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